Sam Brusco, Associate Editor03.10.21
Brainlab acquired Mint Medical, a Heidelberg, Germany-based company that develops image reading and reporting software for clinical routine and research. The deal aims to improve the structured diagnosis, analysis, and treatment of cancer and other diseases.
Using Mint’s software, radiologists are supported while working through an imaging exam in capturing all primary and secondary information relevant to diagnosis and therapeutic decision making. The technology-enabled, context-sensitive way of radiological reporting yields a structured, holistic view on a patient’s situation and clinical history.
“The transformation of our health care system is currently focused in large part on standardizing clinical data through a coding system,” Brainlab president and CEO Stefan Vilsmeier told the press. “However, high quality and consistency of such data requires a validated, reproducible, and structured digital process, for which Mint Medical is setting the benchmark.”
Together, Brainlab and Mint technologies enable linking data across multiple oncological subspecialties, from clinical oncology to surgical oncology and radiotherapy. Integrating patient-reported outcomes measures (PROMs) from VisionTree, (a recent Brainlab acquisition) will further add valuable longitudinal data to the pool available for analysis.
Mint Medical radiology users will additionally benefit from Brainlab expertise in deep integration with a broad spectrum of standards (DICOM, FHIR, HL7) and in hospital information systems. Further process automation allows extracting pre-existing data to prefill certain fields in the structured clinical forms. More automation will be achieved by adding Brainlab Anatomical Mapping and context-based AI algorithms to automatically extract information from diagnostic images, more efficiently linking image data with the structured templates.
“Brainlab brings to Mint a highly compatible entrepreneurial culture, enabling us to more rapidly enhance, scale, and deploy our technology,” commented Matthias Baumhauer, president of Mint Medical. “We are excited about the tremendous opportunities for both our clinical research and clinical routine users.”
The acquisition bolsters Brainlab’s oncology portfolio by frontloading the treatment planning process with more detailed, structured, and clinically relevant information. During tumor board meetings, participants will gain access to standardized reports on radiological findings to support their discussion on patient-specific treatment decisions. Post-treatment, integrating data from oncology and radiology will enhance the follow-up process through a systematic response assessment. In addition to oncology, other subspecialties like spine surgery will benefit from the technology. Structured radiological reports will allow software-driven comparison and therefore independent validation through multiple experts either in the context of a clinical trial or for quality assurance.
Mint Medical clinical trial users will benefit from Brainlab technology for cloud computing, image data analysis, and patient-reported outcomes measures. The two firms aim to jointly improve technological infrastructure for managing clinical trials as well as large scale registries.
Using Mint’s software, radiologists are supported while working through an imaging exam in capturing all primary and secondary information relevant to diagnosis and therapeutic decision making. The technology-enabled, context-sensitive way of radiological reporting yields a structured, holistic view on a patient’s situation and clinical history.
“The transformation of our health care system is currently focused in large part on standardizing clinical data through a coding system,” Brainlab president and CEO Stefan Vilsmeier told the press. “However, high quality and consistency of such data requires a validated, reproducible, and structured digital process, for which Mint Medical is setting the benchmark.”
Together, Brainlab and Mint technologies enable linking data across multiple oncological subspecialties, from clinical oncology to surgical oncology and radiotherapy. Integrating patient-reported outcomes measures (PROMs) from VisionTree, (a recent Brainlab acquisition) will further add valuable longitudinal data to the pool available for analysis.
Mint Medical radiology users will additionally benefit from Brainlab expertise in deep integration with a broad spectrum of standards (DICOM, FHIR, HL7) and in hospital information systems. Further process automation allows extracting pre-existing data to prefill certain fields in the structured clinical forms. More automation will be achieved by adding Brainlab Anatomical Mapping and context-based AI algorithms to automatically extract information from diagnostic images, more efficiently linking image data with the structured templates.
“Brainlab brings to Mint a highly compatible entrepreneurial culture, enabling us to more rapidly enhance, scale, and deploy our technology,” commented Matthias Baumhauer, president of Mint Medical. “We are excited about the tremendous opportunities for both our clinical research and clinical routine users.”
The acquisition bolsters Brainlab’s oncology portfolio by frontloading the treatment planning process with more detailed, structured, and clinically relevant information. During tumor board meetings, participants will gain access to standardized reports on radiological findings to support their discussion on patient-specific treatment decisions. Post-treatment, integrating data from oncology and radiology will enhance the follow-up process through a systematic response assessment. In addition to oncology, other subspecialties like spine surgery will benefit from the technology. Structured radiological reports will allow software-driven comparison and therefore independent validation through multiple experts either in the context of a clinical trial or for quality assurance.
Mint Medical clinical trial users will benefit from Brainlab technology for cloud computing, image data analysis, and patient-reported outcomes measures. The two firms aim to jointly improve technological infrastructure for managing clinical trials as well as large scale registries.